Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Bronwyn E. Rutland x
  • Refine by Access: All Content x
Clear All Modify Search

Abstract

OBJECTIVE To document clinical signs in cats and dogs with Cuterebra infection, determine the outcome of infected animals, and determine whether Yorkshire Terriers were more commonly affected than other breeds of dogs.

DESIGN Retrospective case series.

ANIMALS 22 cats and 20 dogs with Cuterebra infection.

PROCEDURES Medical records of dogs and cats with Cuterebra infection were reviewed for signalment, history, clinical and laboratory findings, treatment, duration of hospitalization, and outcome.

RESULTS Most (16/20 [80%]) of the dogs weighed ≤ 4.5 kg (10 lb), and Yorkshire Terriers were overrepresented (8/20 [40%]), compared with dogs of other breeds. Ten (50%) dogs and 3 (14%) cats had systemic inflammatory response syndrome at the time of initial evaluation, and 8 (40%) dogs but none of the cats had disseminated intravascular coagulation. The overall mortality rate was 17% (7/42), but was higher for dogs (6/20 [30%]) than cats (1/22 [4.5%]). All 6 dogs that died weighed ≤ 4.5 kg and had systemic inflammatory response syndrome, disseminated intravascular coagulation, or both.

CONCLUSIONS AND CLINICAL RELEVANCE Results indicated that Cuterebra infection can cause severe systemic illness in small-breed dogs. Yorkshire Terriers were more commonly affected than were dogs of other breeds and, subjectively at least, appeared to be more likely to develop severe systemic illness.

Restricted access
in Journal of the American Veterinary Medical Association

Abstract

Objective—To evaluate adverse effects and survival times in dogs with osteosarcoma that received a single SC infusion of carboplatin as adjunctive chemotherapeutic treatment following limb amputation or limb-sparing surgery.

Design—Retrospective case series.

Animals—17 client-owned dogs with spontaneously occurring osteosarcoma.

Procedures—Medical records of dogs that underwent limb amputation or limb-sparing surgery followed by a single continuous SC infusion of carboplatin (total dose, 300 mg/m2 infused over 3, 5, or 7 days) were evaluated. Signalment, tumor location, type of surgery (amputation or limb-sparing), duration of carboplatin infusion, results of hematologic and serum biochemical analyses, and adverse effects were recorded. Kaplan-Meier survival analysis was performed.

Results—Median survival time for all dogs was 365 days. Nine dogs had adverse bone marrow–related (hematologic) effects, 1 had adverse gastrointestinal effects, and 7 had infections at the surgical site. No significant differences were detected in survival times of dogs grouped according to tumor location, type of surgery, duration of carboplatin infusion, or development of postoperative infection.

Conclusions and Clinical Relevance—Median survival time and adverse effects in dogs with osteosarcoma that received a single SC infusion of carboplatin over a 3-, 5-, or 7-day period as adjunctive treatment following limb amputation or limb-sparing surgery were comparable to those of previously reported chemotherapy protocols requiring IV drug administration over several weeks. Further investigation is needed to evaluate the efficacy of this protocol as adjunctive treatment for osteosarcoma and other tumors in dogs.

Restricted access
in Journal of the American Veterinary Medical Association